Results 191 to 200 of about 24,412 (283)

Brief report: Meth, tranq, gas station heroin & other drugs complicating addiction treatment

The American Journal on Addictions, Volume 35, Issue 4, Page 543-546, July 2026.
Abstract Background and Objectives Patients using fentanyl have worse treatment outcomes; however, little is known about other drugs that complicate treatment. Methods A national survey (n = 396) was conducted using a random sample of clinicians waivered to prescribe buprenorphine in the United States.
Erin L. Winstanley, Jane M. Liebschutz, Cristina Murray‐Krezan, Galen E. Switzer, Samantha Nash, Sarah Kawasaki   +5 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, Volume 183, Issue 14, Page 4022-4047, July 2026.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

A Phase 1, Open‐Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT This was a Phase 1, open label, randomized, crossover study to evaluate the safety and pharmacokinetics of multiple doses of intranasal naloxone (NCT05377255). Twenty‐four healthy participants were enrolled at a single site in the US to one of two sequences.
David Cassie, Bob Warnock, Faisal Akhtar, Duncan McCloskey, David Wyatt   +4 more
wiley   +1 more source

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

The Detection of Novel Nitazene‐Class Opioids in Unregulated Drug Markets in Canada

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Nitazenes, a highly potent class of synthetic opioids, have emerged in Canadian unregulated drug markets. We report on their presence and composition, along with overdose trends. Methods Samples were obtained from January 2019 to July 2024 from two drug checking services (Toronto's Drug Checking Service (TDCS) and drug checking ...
Emily A. Gelgoot, Kristy M. Scarfone, Nazlee Maghsoudi, Karen McDonald, Wenqing Hao, Cristiana Stefan, Daniel R. Beriault, Sarah R. Delaney, Lianping Ti, Samuel Tobias, Jeanette M. Bowles, Dan Werb, Members of Toronto's Drug Checking Service   +12 more
wiley   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard Le Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer, Jennifer L. Smith, Courtney Weber, Bas W. J. Bens, Daniel M. Fatovich, Shaun L. Greene, Jennifer L. Schumann, Paul Dessauer, Rebekka Syrjanen, Katherine Z. Isoardi, Keith Harris, Sam Alfred, Viet Tran, Ewoud ter Avest   +13 more
wiley   +1 more source

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Uptake of evidence‐based medication for opioid use disorder (MOUD), including buprenorphine–naloxone, remains low despite the expanding US opioid crisis. This study examined participants' and staff perceptions of adopting and delivering buprenorphine–naloxone on a mobile unit providing integrated MOUD and HIV services for people ...
Rose A. Schmidt, Amaya Perez‐Brumer, Peter Davidson, Steve Shoptaw, Nabila El‐Bassel, Philip Andrew, Jayla Harris, Omar Nieto, Sydney Bornstein, Rashaunna Redd, Jessica Yeager, David Goodman‐Meza, Albert L. Hasson, Marc Seigel, Cecile Denis, Renee El‐Krab, Laramie R. Smith, on behalf of the HPTN 094 Team   +17 more
wiley   +1 more source

Price of Nitazenes for Sale on Cryptomarkets and Surface Web Shops

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Nitazenes are potent synthetic opioids increasingly detected in illicit drug markets in Australia and globally. Little is known about the pricing of nitazenes, which can influence patterns of use and accessibility. This study examines the price of nitazenes listed for sale via cryptomarkets and surface web shops.
Nicola Man, Monica J. Barratt, Raimondo Bruno, Connor Graham, Vandit Sadaphale, Amy Peacock, Rachel Sutherland   +6 more
wiley   +1 more source